Summary:
A phase iii, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of two fixed dose combinations of aclidinium bromide/formoterol fumarate compared with aclidinium bromide, formoterol fumarate and placebo for 24-weeks treatment in patients with moderate to severe, stable chronic obstructive pulmonary disease (copd).
Qualified Participants Must:
• Be at least 40 years of age
•
Be a current or former cigarette smokers with a cigarette smoking history
•
Have a diagnosis of stable moderate to severe COPD.
Qualified Participants May Receive:
All study related medication and care at no cost. Eligible participants will be compensated for time and travel.